Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) — The global autoinjectors market, valued at US$1.08 billion in 2023, stood at US$1.40 billion in 2024 and is projected to advance at a resilient CAGR of 13.6% from 2024 to 2030, culminating in a forecasted valuation of US$3.02 billion by the end of the period. The autoinjector finished formulations market is estimated to reach USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.
What is driving this surge? Technological advancements in device design, integration of connectivity features, and rising incidence of severe allergies and chronic diseases are reshaping drug delivery. Regulatory approvals for biologics such as Humira and emerging categories like GLP-1 receptor agonists are further catalyzing adoption.
Why does this matter now? As healthcare systems worldwide emphasize patient-centric care and at-home treatment, autoinjectors are becoming indispensable for self-administration, improving compliance, and reducing hospital dependency.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724
Key Growth Drivers
- Ease of Use & Accessibility – Simplified administration encourages wider adoption among patients and healthcare providers.
- Biologics & Biosimilars Pipeline – Approvals and launches are expanding therapeutic applications.
- Smart Technology Integration – Features such as Bluetooth connectivity, dose monitoring, and adherence tracking are redefining patient engagement.
Technology & Usage Trends
How is the technology evolving? The market is segmented into manual and automatic autoinjectors. Manual devices, valued for cost-effectiveness and user control, are projected to record the highest CAGR. Automatic models are also gaining traction with support from regulatory bodies and new …